Profusa shareholders approve reverse stock split, asset acquisition, and equity plan amendments

Profusa, Inc.

Elected Lauren Chung as Class I director with 631,502 FOR votes.
Approved reverse stock split (1:5 to 1:200) at board's discretion through June 2028.
Approved issuance of convertible preferred stock and common shares to Bio Insights LLC for PanOmics Assay acquisition.
Approved potential >19.99% share issuance upon conversion of promissory note to NorthView Sponsor I LLC.
Approved increase in 2025 Equity and Incentive Plan shares from 100,386 to 795,930.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.